7:21 PM Β· 10 February 2025

Springworks Therapeutics surges 36% amid acquisition speculation by Merck πŸ”ŽπŸ“ˆ

Merck KGaA (MRCG.DE), the German healthcare and technology company, is in advanced negotiations to acquire U.S.-based Springworks Therapeutics (SWTX.US), a biotech firm specializing in cancer and rare disease treatments. According to sources familiar with the matter, a deal could be finalized in the coming weeks, although terms of the potential agreement have not been disclosed.

Following the news, Springworks' stock surged almost 40% before stabilizing at a 36% gain, reflecting strong investor interest. Springworks, which has a market capitalization of approximately $4 billion, has developed Ogsiveo, a monotherapy drug approved in the U.S. for the treatment of desmoid tumors. The potential acquisition would strengthen Merck's oncology pipeline.

Uncertain Outcome and Industry Interest

While negotiations between Merck and Springworks have progressed, sources caution that other potential buyers may still emerge. Springworks has previously been the subject of takeover speculation, with reports last year suggesting interest from Swiss pharmaceutical firms and AbbVie (ABBV.US).

Merck declined to comment on the discussions but stated that it "continuously assesses options that could support its businesses and strategic positioning." Springworks has also declined to provide a statement regarding the potential deal.

11 September 2026, 3:01 PM

US OPEN: Rebound on Wall Street despite higher Supercore inflation and a jump in yields

11 September 2026, 2:08 PM

Oracle earnings: Good, but it could have been better.

11 September 2026, 12:24 PM

Adobe Delivers Strong Results, but Falls Short of Expectations. The Market Fears the Impact of AI

10 September 2026, 7:01 PM

Daily Summary: Indices Pull Back Under Pressure from Oil Prices

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the ComissΓ£o de Valores MobiliΓ‘rios (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits